U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449 FEB 1 7 2004

Sheet \_1\_ of \_1\_

ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS
FILING DATE:	May 10, 2002	GROUP: 1645

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
14	₩.					,	(ii apprount)
1	<b>(B</b> )						
P	VC						
A	Q						

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n )
BA						
88	,			<del> </del>		
BC						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

VSY	CA	Bolay, H., et al., "Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model" <i>Nature Medicine</i> , Vol 8, No. 2, February 2002, pp 136-142
	СВ	1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1
	CC	
	CD	
	CE	
	CF	
	CG	
	СН	
	CI	
	ÇJ	
	CK	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SPAL 7/04

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
POPM PTO 1440

Sheet 1 of 1

ATTY. DOCI	KET:	17500 (BOT)		T CITED BY APP				
····			TPE	SERIAL NO.: 10/143,078				
APPLICANT	<u></u>	STEPHEN DONOY		TITLE: THERAPEUTIC TREATMENTS FOR RECENEUROPSYCHIATRIC DISORDERS				
FILING DAT	E:	May 10, 2002	30 0 3 2003	GROUP: 1645			SEP 1 0	
			U.S. PAT	ENT DOCUMENTS			ECH CENTER	
'EXAMINER INITIAL	AA	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)	
	AB						,	
	AC		ļI					
	AD							
•	<u> </u>	<u>I </u>	FOREIGN PA	TENT DOCUMENTS	3			
		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO	
Q-f	BA	DE10150415A1	5/2003	Germany			(yes/no) Yes First and last	
10-1	ВВ		1		+		page	
	BC							
_		(Includi		HER ART , Date, Pertinent Pag	jes, etc.)			
(6)	CA	Cereda, E., et al dementia disorde	., Medicinal c ers: <i>Eur J Dr</i>	chemistry of musc ug Metab Pharma	arinic agon	ists for the tre	eatment of	
U	CB	cells; <i>Moving Dis</i>	l J. et al., A s <i>orders</i> : 1995	survey of botulinur 5. May:10/3):376	n neurotoxi	n substrate e	xpression in	
	CC T	Sramka, M., et a	Long-term	results in patients Bratisl. Lek. List	s with stere	otaxic surger	y for	
	CD	E-73.10Patilologic	Z 013010618	, Diausi, Lek. List	, <del>9</del> 3, 1992:	/; pgs. 364-3	866	
	CE							
	CF							
	CG					-		
	СН							
	CI							
- 19	تا		· · · · · · · · · · · · · · · · · · ·				<del></del>	

# BEST AVAILABLE COPY

EXAMINER SPORT	DATE CONSIDERED	3/2004
*EXAMINER: Initial if reference considered, whether or conformance and not considered. Include conv of this form	not citation is in conformance with MPEP 609. De	aw line through citation if not in
conformance and not considered. Include copy of this form	with next communication to applicant.	aw mic alongit citation in mot in
$\langle A_{\alpha} \rangle_{\alpha}$	7	•

OEPARTMENT OF COMMER ATENT AND TRADEMARK OFF	Œ
ATENT AND TRADEMARK OFF	Œ
OPM PTYLIAAO	

Sheet	. 1	of	1
		<b>~</b> _	

	LIST OF ART CITED BY APPLICANT					
ATTY. DOCKET	17500 (BOT)	SERIAL NO.: 10/143,078				
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS				
FILING DATE:	May 10, 2002	GROUP: 1645				

#### U.S. PATENT DOCUMENTS

'EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
/ 1	AA					. ,	
,	AB	·					
	AC						
	AD			. To 18 (18 4)			

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
 ВА					·	
BB						
ВС				•		

OTHER ART
(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Bolay, H., et al., "Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model" <i>Nature Medicine</i> , Vol 8, No. 2, February 2002, pp 136-142
	СВ	
•	CC	
	CD	
,	CE	
	CF	
	CG	
	СН	
	CI	
	cu	
	СК	

		<i>f</i>	7/18/
EXAMINER	$\frac{1}{2}$	DATE CONSIDERED	
*EXAMINER- Initial if	reference considered	Whether or not citation is in conformance with MDED 60	Or Denny line through pitation if

conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND FORM PTO-14

FORM PTO-1449	EMARK OFFICE		۵	77
		IST OF ART C	ITED BY APPLICANT	My Ch
ATTY. DOCKET:	17500 (BOT)	OIPE	SERIAL NO.: 10/143,078	1/2 mg/2
APPLICANT:	STEPHEN DONOV	### ## D ==== >1	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS	10000
FILING DATE:	May 10, 2002	Bran Sell	GROUP: 1645	

Sheet \_1\_ of \_\_\_\_\_

#### **U.S. PATENT DOCUMENTS**

"EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
AA			7			(ii applicatio)
AB						
AC			<del></del>			·
AD				<del></del>		

#### FOREIGN PATENT DOCUMENTS

	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BA		1			
88					
BC					·

OTHER ART
(Including Author, Title, Date, Pertinent Pages, etc.)

18	CA	Cosgrove, G. Rees, et al., <i>Cingulotomy in Psychosurgery</i> , Chpt. 203, pp. 1965-1979; Stereotactic and Functional Neurosurgery, 1998, P. L. Gildenberg, Ed., McGraw-Hill Pub.
V	CB	Hussain, E.S., et al., A cohort study of psychosurgery cases from a defined population, J. Neurol Neurosurg Psychiatry, 1988 Mar;51(3):345-52
	cc	Kim, C.H., et al., Anterior cingulotomy for refractory obsessive-compulsive diso, Acta Psychiatr Scand. 2003 Apr; 107(4):283-90
	CD	Kim, M.C., et al., Review of long-term results of stereotactic psychosurgery, Neurol Med Chir (Tokyo) 2002 Sep;42(9):365-71
	CE	Sramka, M., et al., Long-term resuls in patients with stereotaxic surgery for psychopathologic disorders, Bratisl Lek Listy 1992 Jul:93(7):364-6 - English Abstract enclosed with Article.
	CF	Yoshimura, D.M., et al., <i>Treatment of Hemifacial Spasm with Botulinum Toxin</i> , Muscle Nerve 1992;15(9): 1045-9
	f CG	Yu Y.L., et al., Treatment of idiopathic hemifacial spasm with botulinum toxin, Acta Neurol Scand 1992;85(1):55-57
	СН	
	CI	
	ယ	
	СК	

**EXAMINER** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw life through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

U.S. DEPARTMENT	T OF COMMERC
PATENT AND TRA	DEMARK OFFIC
FORM PTO 1440	



Sheet \_\_1\_\_ of \_\_4\_\_

	ALISI OF AF	RT CITED BY APPLICANT	
ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078	
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TO NEUROPSYCHIATRIC DISC	REATMENTS FOR RECEIVE
FILING DATE:	May 10, 2002	GROUP: 161/1645	JUL 3 1 2002
		TENT DOCUMENTS	TECH CENTER 1600/2
*EXAMINER	DOCUMENT NO. DATE	NAME CLASS	STIP CLASS   SHING DATE

					CON CEIMITH IC
	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
Į			<u> </u>		- (if applicable)
	11/23/99	Foster, et al.			
1	1 1-				

INITIAL		OGGGMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
(FSD)	AA	5,989,545	11/23/99	Foster, et al.			
4	AB	6,306,403 B1	10/23/01	Denovan	1 Car	se 1) .	
	AC	6,306,423 B1	10/23/01	Donovan, et al.	1		
<b>V</b>	AD	·			- <del>  - V -</del>		
			FOREIGN P	ATENT DOCUMENTS	<del></del>	<u> </u>	

#### DOCUMENT NO. COUNTRY DATE CLASS SUB-CLASS TRANSLATION (yes/no) BA ВВ ВС

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

60	CA	Bejjani, B. et al., Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance, J. Neurosurg 92:615-625, April 2000
	ÇB	Bellezza, D., et al., Stereotactic Interstitial Brachytherapy, Text book of stereotactic and functional neurosurgery, McGraw-Hill, 1998, Chp. 66, pgs. 577-580
	cc	Bigalke, H., et al., Tetanus Toxin and botulinum a toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord, Naunyn-Schmiedeberg's Arch Pharmacol (1981) 316:244-251
	CD	Bigalke, H., et al., Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture, Brain Research, 360 (1985) 318-324
	CE	Brem, H., et al., The safety of interstitial chemotherapy with BCNU-loaded polymer follwed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial, J. of Neuro-Oncology 26:111-123, 1995
	CF	Brem, H., et al., Placebo-controlled trial of saety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, The Lancet, Vol. 345, April 22, 1995, pgs. 1008-1012
	CG	Burr Leiva, Daniel, <i>The neurochemistry of mania: a hypothesis of etiology and a rationale for treatment</i> , Prog. Neuro-Psychopharmacol & Biol. Psychiat. 1990, Vol. 14, pp 423-429

$Q \sim Q \sim 1$		- 1	
EXAMINER (9)//	DATE CONSIDERED	2/2004	
*EXAMINER: Initial if reference considered, whether or not citation	is in conformance with MARCH COO.	Draw line through citation if no	nt in
conformance and not considered. Include copy of this form with next	communication to applicant.	Tanana and an analas an an	


BEST AVAILABLE COPY

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

ATTY. DOCKET:

APPLICANT:

FILING DATE:



120	CH	Cereda, E., et al., Medicinal chemistry of muscarinic agonists for the treatment of
LVX7_		dementia disorders, Eur J. Drug Metab Pharmacokinet 1994, Jul-Sep; 19(3): 179-83
P	CI	Clarke, P., et al., Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological
		evidence, Neuroscience Vol. 23, No. 3, pp 1011-1019, 1987
	ပ	Cummings, J. L., et al., Alzheimer's disease: cognitive and behavioral
<u>_</u>		pharmacotherapy, Connecticut Medicine, Sept 1997, Vol. 61, No. 9, pp. 543-552
I = I	CK	Fung, L.K., et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-
1 /	1	hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer
		implant in the monkey brain, Cancer Research, 58, 672-684, Feb 15, 1998,
	CL	Garcia-Rill, E., et al., <i>Mesopontine neurons in schizophrenia</i> , Neuroscience Vol. 66, No. 2, pp 321-335, 1995
	СМ	Gaspar, L.E., et al., Permanent lodine implants for recurrent malignant gliomas, Int.
		J. Radiation Onocology Biol. Phys., Vol. 43, No. 5, pp 977-982, 1999
	CN	German, D.C., et al., Mesopontine cholinergic and non-cholinergic neurons in
	·	Schizophrenia, Neuroscience, Vol. 94, No. 1, pp. 33-38, 1999
	co	Gonelle-Gispert, C., et al., SNAP-25a and -25b isofoms are both expressed in
		insulin-secreting cells and can function in insulin secretion, Biochem. J. (1999) 339; pp. 159-165
	CP	Habermann, E., et al., Tetanus toxin and botulinum A and C neurotoxins inhibit
		noradrenaline release from cultured mouse brain, J. Neurochemistry, 1988, pp. 522-527
	Q	Habermann, E., I-Labeled Neurotoxin from Clostridium botulinum A: preparation,
		binding to synaptosomes and ascent to the spinal cord, Naunyn-Schmiedeberg's Arch. Pharmacol. 281, 47-56 (1974)
	CR	Habermann, E., Inhibition by tetanus and botulinum A toxin of the release of
		[ <sup>3</sup> H]noradrenaline and [ <sup>3</sup> H]GABA from rat brain homogenate, Experientia 44 (1988) pp 224-226
	cs	Hamson's Principles of Internal Medicine, 1988, 14th Edition, McGraw-Hill, Table
	OT.	365-8
	CT "	Jankovic, J., et al., <i>Therapy with Botulinum Toxin,</i> Marcel Dekker, Inc. 1994, pg. 150.
/	ÇU	Jankovic, J., et al., Therapy with Botulinum Toxin, Marcel Dekker, Inc. 1994, pg. 5.
	CV	Levy, M.L., et al., Neuropsychiatric Symptons and Cholinergic Therapy for
		Alzheimer's Disease,, Gerontology, 1999;45(suppl 1) 15-22

**EXAMINER** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this formation is in communication to applicant.

BEST AVAILABLE COPY

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449



# SheenEGE(VED

LIST OF STIT CITED BY APPLICANT

JUL 3 1 2002

ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078  TECH CENTED 1600/2000
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS
FILING DATE:	May 10, 2002	GROUP: 1614 1645

CX   Marchese Ragona, R., et al. Management of Parotid Sialocele with Botulinum Toxin, The Laryngoscope 109, Aug 1999, pp. 1344-1346			
CX Marchese Ragona, R., et al. Management of Parotid Sialocele with Botulinum Toxin, The Laryngoscope 109, Aug 1999, pp. 1344-1346  CY Meltzer, H., et al., The dopamine hypothesis of schizophrenia: a review, Schizophrenia Bulletin, Vol. 2, No. 1, 1976, pp. 19-76  CZ Moyer, E., et al., Botulinum Toxin Type B: Experimental and Clincal Experience, Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85  CAA Movement Disorders, Vol. 10, No. 3, 1995:376  CBB Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  Scharfen, C.O., et al., High activity lodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CIX Sioop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in	VEB	cw	Marjama-Lyons, J., et al., <i>Tremor-Predominant Parkinson's Disease</i> , Drugs & Aging 2000 Apr; 16(4); 273-278
Meltzer, H., et al., The dopamine hypothesis of schizophrenia: a review, Schizophrenia Bulletin, Vol. 2, No. 1, 1976, pp. 19-76  CZ Moyer, E., et al., Botulinum Toxin Type B: Experimental and Clincal Experience, Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85  CAA Movement Disorders, Vol. 10, No. 3, 1995:376  CBB Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Scharter, C.O., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84		CX	Marchese Ragona, R., et al. Management of Parotid Sialocele with Botulinum
Schizophrenia Bulletin, Vol. 2, No. 1, 1976, pp. 19-76  CZ Moyer, E., et al., Botulinum Toxin Type B: Experimental and Clincal Experience, Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85  CAA Movement Disorders, Vol. 10, No. 3, 1995:376  CBB Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CI Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in		CY	Meltzer H. et al. The donamine hypothesis of schizophronia. a review
CZA Moyer, E., et al., Botulinum Toxin Type B: Experimental and Clincal Experience, Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85  CAA Movement Disorders, Vol. 10, No. 3, 1995:376  Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in			Schizophrenia Bulletin, Vol. 2, No. 1, 1976, pp. 19-76
Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85  CAA Movement Disorders, Vol. 10, No. 3, 1995:376  CBB Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CII Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84	1 1	CZ	Moyer, E., et al., Botulinum Toxin Type B: Experimental and Clincal Experience.
CAA Movement Disorders, Vol. 10, No. 3, 1995:376  CBB Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CHH Scharten, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84			Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85
Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CUI Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84		CAA	Movement Disorders, Vol. 10, No. 3, 1995;376
palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115  CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharten, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CIJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84		CBB	Naumann, M., et al., Botulinum toxin type a in the treatment of focal, exillent and
CCC Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CXX Sioop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in			palmar hyperhidrosis and other hyperhidrotic conditions. European Journal of
enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CXX Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in	<del>  </del>	CCC	Neurology 1999, 6 (suppl 4) 5111-5115
Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.  CDD Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CJJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84	1 1	•••	Nowinski, W.E., et al., Computer-Alded Stereotactic functional neurosurgery
Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, Ann Neurol 1999;46:249-252  Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CIJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84	1 1	1	ennanced by the use of the multiple brain atlas database, IEEE Transactions on
patients with essential tremor, Ann Neurol 1999;46:249-252  CEE Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84		COD	Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.
Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412  CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CIJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84		1000	Panapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in
CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in		1	patients with essential tremor, Ann Neurol 1999;46:249-252
CFF Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in	.	CEE	Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic
Guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-81  CGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CAU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84	ļ	1 655	<i>science and medicine</i> , Toxicon 1997;35(9):1373-412
GGG Sarter, M., et al., Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84		CFF	Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from
CHH Schartz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CIJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84			<i>guinea-pig cerebral cortical synaptosomes</i> , Eur J. Biochem 1987 Jun: 165(3):675-
acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82  CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in		CGG	Sarter, M., et al., Basal forebrain afferent projections modulating cortical
CHH Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-9  CII Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CLU Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in			acetylcholine, attention, and implications for neuropsychiatric disorders. ANN NY
Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CJJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in	<del></del>	СНН	Schantz, E.J. et al. Properties and use of hotulinum toxin and other startlet
Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J. Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591  CJJ Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in	1		Deurotoxins in medicine. Microbiological Reviews Mar 1000: Val. 56. No. 4
Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591		CII	Scharfen CO et al. High activity indine 125 interetitiel implementary.
Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II, Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in			Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591
Plenum Press (1996) pp. 63-84  CKK Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in		cu	Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II
Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in			Plenum Press (1996) pp. 63-84
V I have an a let have a second of the secon	1/	СКК	Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potenticy in
\	\ <i>X</i>		humans if it is refrozen or refrigerated for 2 weeks before use. Neurology
1997,48:249-253	V		1997,48:249-253

EXAMINER DATE CONSIDERED 3 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7/04

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FÖRM PTO-1449



# SheRECENVED

JUL 3 1 2002

	Whisi or and	CHED DI AFFLICANI	
ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078	TECH CENTER 1600/2900
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TO NEUROPSYCHIATRIC DISC	
FILING DATE:	May 10, 2002	GROUP: 1614 (64)	_

180		Tandon, R., et al., <i>The cholinergic system in schizophrenia reconsidered:</i> anticholinergic modulation of sleep and symptom profiles, Neuropsychopharmacology 1999, Vol. 21, No. S6 pp. S189-S202
V	CMM	Teipel, S.J., et al., In Vivo neuroreceptor imaging and applications for alzheimer's disease, Drug News Perspect 12(6) July 1999, pp. 341-350
		White, K.E., et al., Schizophrenia and Alzheimer's Disease: clinical and pathophysiologic analogies, Comprehensive Psychiatry, Vol. 37, No. 3 (May/June) 1996, pp 188-195
	coo	Weigand, H., et al., <i>I-Labelled Botulinum A Neurotoxin: pharmacokinetics in cats after intramuscular injection</i> , Naunyn-Schmiedeberg's Arc. Pharmacol. 292, 161-165 (1976).

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.